Evidence map›Paper›PMID 35949665›Full record

ArticleHepatology forum2020

From cirrhosis to hepatocellular carcinoma: An investigation into hepatitis C viral oncogenesis.

Jihad Aljabban, Nilay Danis, Merve Gurakar, Kamal Khorfan, Nabeal Aljabban, Cem Simsek, Hussam Salhi, Maryam Panahiazar, Dexter Hadley, Ahmet Gurakar and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology forum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jihad AljabbanOhio State University College of Medicine, Columbus, Ohio, USA.
Nilay DanisDepartment of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Merve GurakarDepartment of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Kamal KhorfanHenry Ford Health Systems, Detroit, Michigan, USA.
Nabeal AljabbanPenn State College of Medicine, Hershey, Pennsylvania 17033.
Cem SimsekDepartment of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Hussam SalhiOhio State University College of Medicine, Columbus, Ohio, USA.
Maryam PanahiazarInstitute for Computational Health Sciences, University of California, San Francisco, California 94158.
Dexter HadleyInstitute for Computational Health Sciences, University of California, San Francisco, California 94158.
Ahmet GurakarDepartment of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Behnam SaberiIcahn School of Medicine at Mount Sinai Division of Liver Diseases, New York, New York, USA.
The Ohio State University · US

Funding

Crowd-Assisted Deep Learning (CrADLe) Digital Curation to Translate Big Data into Precision MedicineU01LM012675 · NLM · UNIVERSITY OF CENTRAL FLORIDA · PI HADLEY, DEXTER D · 2017 to 2020
$2.1M
Crowd-sourcing A STAR Functional Genomic Characterization of Cancer with Open Big DataUH2CA203792 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HADLEY, DEXTER D · 2016 to 2017
$634k
NCI NIH HHS UH2 CA203792NLM NIH HHS U01 LM012675
6 · The paper itself

Abstract

Background and Aim: Hepatitis C is a leading cause of chronic liver disease and hepatocellular carcinoma (HCC). Understanding the evolution and biology of HCC among HCV patients may lead to novel therapeutic avenues and risk stratification. Material and Methods: Using meta-analysis platform STARGEO, we performed two separate meta-analyses as follows: 357 HCV-related HCC tumor samples with 220 adjacent non-tumor samples and 92 HCV-related cirrhotic liver samples with 53 healthy liver samples as a control. Then, we analyzed the signature in Ingenuity Pathway Analysis. Results: HCV cirrhosis analysis demonstrated LPS/IL-1 mediated inhibition of RXR function, LXR/RXR activation, sirtuin signaling, IL-10 signaling and hepatic fibrosis/stellate cell activation as top canonical pathways. IL1β, TNF, and TGF-β1 were top upstream regulators. Cellular morphologic and signaling changes were noted through the up-regulation of RGS1/2, WNT receptor FZD7, the TGF-β1-induced gap junction gene GJA1, and the zinc finger transcription factor repressor SNAI2. Apoptosis was inhibited through the down-regulation of OMA1. Metabolic dysfunction was noted through the down-regulation of SCLY and CBS. HCV-related HCC analysis showed FXR/RXR and LXR/RXR signaling, LPS/IL1-mediated inhibition of RXR activation, and melatonin degradation as top canonical pathways. Conclusion: Our results suggest that the genetic changes in the setting of chronic HCV infection predispose patients to developing HCC.

Indexed as

HCCHCVSTARGEO

Identifiers

PMID35949665
PMCPMC9344372
OpenAlexW3002950920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.